Research Progress of PRMT5 in Gynecological Malignant Tumors

doi:10.12280/gjszjk.20240518

Abstract

Abstract:

Protein arginine methyltransferase 5 (PRMT5), a major member of the PRMT family, catalyzes the methylation of arginine residues in both histone and non-histone proteins. PRMT5 is involved in many biological processes such as transcription, RNA splicing, DNA repair, and cell cycle control. Current studies have shown that PRMT5 is closely related to the occurrence and development of human malignant tumors and plays a similar role as an oncogene. Ovarian cancer, cervical cancer and endometrial cancer, as the three major gynecological malignancies, pose a serious threat to women's life and health. The up-regulated PRMT5 in ovarian cancer, cervical cancer and endometrial cancer can promote the clonal formation, DNA replication and proliferation of tumor cells. By regulating the tumor cell migration in an EMT-dependent manner, PRMT5 can enhance the stability and expression of programmed death ligand-1 (PD-L1) on cervical cancer cells, thus promoting tumor immune escape. In addition, PRMT5 inhibitor combined with epigenetic drugs can promote tumor cell senescence, enhance the chemotherapy sensitivity of ovarian cancer cells to docetaxel, cooperate with poly (ADP-ribose) polymeras (PARP) inhibitors to inhibit the growth and proliferation of ovarian cancer cells, and reduce the adverse reactions caused by PARP inhibitors, suggesting that PRMT5 inhibitor can be used for maintenance treatment of ovarian cancer. It is expected to provide new ideas for the treatment and prognosis of gynecological malignant tumors.

Key words: Protein-arginine N-methyltransferases, Uterine cervical neoplasms, Ovarian neoplasms, Endometrial neoplasms, Epithelial-mesenchymal transition

SONG Meng-meng, CHEN Fang, BAO Xiang-xiang, TIAN Xin-li. Research Progress of PRMT5 in Gynecological Malignant Tumors[J]. Journal of International Reproductive Health/Family Planning, 2025, 44(2): 171-176.

References 42

[1]	刘权, 王璐璐, 徐骏宇, 等. 基于蛋白质组学的组蛋白表观遗传酶抑制剂研究进展[J]. 药学学报, 2023, 58(9):2541-2550. doi: 10.16438/j.0513-4870.2022-0937.
[2]	Hwang JW, Cho Y, Bae GU, et al. Protein arginine methyltransfe-rases: promising targets for cancer therapy[J]. Exp Mol Med, 2021, 53(5):788-808. doi: 10.1038/s12276-021-00613-y. pmid: 34006904
[3]	许雪萌, 崔适文, 张文龙, 等. 表观遗传修饰在肿瘤代谢重编程中的作用和机制[J]. 肿瘤药学, 2023, 13(6):686-692. doi: 10.3969/j.issn.2095-1264.2023.06.05.
[4]	Wu Q, Schapira M, Arrowsmith CH, et al. Protein arginine methylation: from enigmatic functions to therapeutic targeting[J]. Nat Rev Drug Discov, 2021, 20(7):509-530. doi: 10.1038/s41573-021-00159-8. pmid: 33742187
[5]	Ghosh SK, Paik WK, Kim S. Purification and molecular identifica-tion of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme[J]. J Biol Chem, 1988, 263(35):19024-19033. doi: 10.1016/S0021-9258(18)37384-8. pmid: 2461933
[6]	Lee J, An S, Lee SJ, et al. Correction: Lee et al. Protein Arginine Methyltransferases in Neuromuscular Function and Diseases. Cells 2022, 11, 364[J]. Cells, 2022, 11(16):2609. doi: 10.3390/cells11162609.
[7]	Chang K, Gao D, Yan J, et al. Critical Roles of Protein Arginine Methylation in the Central Nervous System[J]. Mol Neurobiol, 2023, 60(10):6060-6091. doi: 10.1007/s12035-023-03465-x. pmid: 37415067
[8]	Kim H, Ronai ZA. PRMT5 function and targeting in cancer[J]. Cell Stress, 2020, 4(8):199-215. doi: 10.15698/cst2020.08.228. pmid: 32743345
[9]	王雅君, 曹建博, 何潇潇. 精氨酸甲基转移酶5在神经系统发育及相关疾病中的功能[J]. 生理科学进展, 2024, 55(5):415-422. doi: 10.20059/j.cnki.pps.2024.07.1080.
[10]	Cox J, Esser LM, Jüdt M, et al. NF90/NFAR (nuclear factors associated with dsRNA) - a new methylation substrate of the PRMT5-WD45-RioK1 complex[J]. Biol Chem, 2022, 403(10):907-915. doi: 10.1515/hsz-2022-0136.
[11]	Asberry AM, Cai X, Deng X, et al. Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors[J]. J Med Chem, 2022, 65(20):13793-13812. doi: 10.1021/acs.jmedchem.2c01000. pmid: 36206451
[12]	Musiani D, Bok J, Massignani E, et al. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity[J]. Sci Signal, 2019, 12(575):eaat8388. doi: 10.1126/scisignal.aat8388.
[13]	Motolani A, Martin M, Sun M, et al. The Structure and Functions of PRMT5 in Human Diseases[J]. Life(Basel), 2021, 11(10):1074. doi: 10.3390/life11101074.
[14]	Sun Y, Jin X, Meng J, et al. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression[J]. EMBO J, 2023, 42(23):e114558. doi: 10.15252/embj.2023114558.
[15]	Liu A, Yu C, Qiu C, et al. PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis[J]. Oncogene, 2023, 42(19):1572-1584. doi: 10.1038/s41388-023-02674-x.
[16]	Bate-Eya LT, Albayrak G, Carr SM, et al. Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma[J]. Mol Oncol, 2024 Jul 17. doi: 10.1002/1878-0261.13702.
[17]	樊聪, 汪家佳, 王廷, 等. PRMT5调控m⁶A修饰介导三阴性乳腺癌细胞对多柔比星敏感性的机制研究[J]. 空军军医大学学报, 2024, 45(7):788-795. doi: 10.13276/j.issn.2097-1656.2024.07.011.
[18]	包香香, 张瑞, 王子超, 等. PRMT5对卵巢癌细胞增殖及侵袭转移能力的影响[J]. 现代妇产科进展, 2018, 27(2):90-94. doi: 10.13283/j.cnki.xdfckjz.2018.02.002.
[19]	Xie F, Zhang H, Zhu K, et al. PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1[J]. MedComm(2020), 2023, 4(2):e245. doi: 10.1002/mco2.245.
[20]	Mei S, Ge S, Wang J, et al. PRMT5 promotes progression of endometrioid adenocarcinoma via ERα and cell cycle signaling pathways[J]. J Pathol Clin Res, 2021, 7(2):154-164. doi: 10.1002/cjp2.194.
[21]	耿玉娥, 仇春侠, 李卫平, 等. 石见穿多糖通过调控circ-PRMT5/miR-432-5p轴对宫颈癌细胞增殖和凋亡的影响[J]. 中国性科学, 2022, 31(6):27-30. doi: 10.3969/j.issn.1672-1993.2022.06.008.
[22]	Liu JH, Cao YM, Rong ZP, et al. Trichostatin A Induces Autophagy in Cervical Cancer Cells by Regulating the PRMT5-STC1-TRPV6-JNK Pathway[J]. Pharmacology, 2021, 106(1/2):60-69. doi: 10.1159/000507937.
[23]	魏野, 王冉冉, 韩田田, 等. 蛋白质精氨酸甲基转移酶5对人卵巢癌HO8910细胞增殖能力的影响[J]. 医学研究生学报, 2018, 31(6):565-572. doi: 10.16571/j.cnki.1008-8199.2018.06.002.
[24]	梅术煜. PRMT5在子宫内膜癌中的作用及机制研究[D]. 济南: 山东大学, 2018. doi: 10.7666/d.Y3409034.
[25]	Jiang Y, Yuan Y, Chen M, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression[J]. Theranostics, 2021, 11(18):9162-9176. doi: 10.7150/thno.59605. pmid: 34522232
[26]	刘铸. 肺癌驱动基因LKB1突变影响IFN-γ-JAK1-Stat1通路活性导致PD-L1表达降低[D]. 广州: 南方医科大学, 2020.
[27]	Mozooni Z, Golestani N, Bahadorizadeh L, et al. The role of interferon-gamma and its receptors in gastrointestinal cancers[J]. Pathol Res Pract, 2023,248:154636. doi: 10.1016/j.prp.2023.154636.
[28]	Liang L, Yue C, Li W, et al. CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3β-PD-L1 axis[J]. Heliyon, 2024, 10(19):e37958. doi: 10.1016/j.heliyon.2024.e37958.
[29]	Brabletz S, Schuhwerk H, Brabletz T, et al. Dynamic EMT: a multi-tool for tumor progression[J]. EMBO J, 2021, 40(18):e108647. doi: 10.15252/embj.2021108647.
[30]	Babaei G, Aziz SG, Jaghi N. EMT, cancer stem cells and autophagy; The three main axes of metastasis[J]. Biomed Pharmacother, 2021,133:110909. doi: 10.1016/j.biopha.2020.110909.
[31]	Saitoh M. Transcriptional regulation of EMT transcription factors in cancer[J]. Semin Cancer Biol, 2023, 97:21-29. doi: 10.1016/j.semcancer.2023.10.001. pmid: 37802266
[32]	Yin X, Teng X, Ma T, et al. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis[J]. Cell Death Differ, 2022, 29(11):2203-2217. doi: 10.1038/s41418-022-01010-2. pmid: 35534547
[33]	Gao J, Liu R, Feng D, et al. Snail/PRMT5/NuRD complex contrib-utes to DNA hypermethylation in cervical cancer by TET1 inhibition[J]. Cell Death Differ, 2021, 28(9):2818-2836. doi: 10.1038/s41418-021-00786-z.
[34]	赵康容, 孙爱琴, 林琼, 等. 蛋白质精氨酸甲基转移酶5促进人卵巢癌HO8910细胞迁移[J]. 江苏大学学报(医学版), 2020, 30(5):430-434. doi: 10.13312/j.issn.1671-7783.y200092.
[35]	Guan Y, Liu X, Tian J, et al. CCL5 promotes the epithelial-mesenchymal transition of circulating tumor cells in renal cancer[J]. J Transl Med, 2024, 22(1):817. doi: 10.1186/s12967-024-05297-2. pmid: 39227943
[36]	Hu Z, Sui Q, Jin X, et al. IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma[J]. J Exp Clin Cancer Res, 2024, 43(1):63. doi: 10.1186/s13046-024-02989-x. pmid: 38424624
[37]	王美达. 组蛋白去乙酰化酶抑制剂SAHA联合PRMT5抑制剂抑制宫颈癌HeLa细胞增殖的机制研究[D]. 长春: 东北师范大学, 2022.
[38]	金男, 杨洪艳, 裴会, 等. 敲低PRMT5对卵巢癌细胞多西紫杉醇化疗敏感性的影响及其机制[J]. 山东医药, 2022, 62(16):48-53. doi: 10.3969/j.issn.1002-266X.2022.16.011.
[39]	Igarashi H, Kuwahara K, Yoshida M, et al. GANP suppresses the arginine methyltransferase PRMT5 regulating IL-4-mediated STAT6-signaling to IgE production in B cells[J]. Mol Immunol, 2009, 46(6):1031-1041. doi: 10.1016/j.molimm.2008.08.272. pmid: 19181385
[40]	O'Brien S, Butticello M, Thompson C, et al. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer[J]. BMC Cancer, 2023, 23(1):775. doi: 10.1186/s12885-023-11260-z. pmid: 37596538
[41]	Li Y, Dobrolecki LE, Sallas C, et al. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition[J]. Cell Rep Med, 2023, 4(12):101326. doi: 10.1016/j.xcrm.2023.101326.
[42]	Carter J, Hulse M, Sivakumar M, et al. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies[J]. Cancer Res Commun, 2023, 3(11):2233-2243. doi: 10.1158/2767-9764.CRC-23-0070.